FI913275A - Foerfarande foer foerbaettring av sjukdomsmottstaondskraft. - Google Patents

Foerfarande foer foerbaettring av sjukdomsmottstaondskraft. Download PDF

Info

Publication number
FI913275A
FI913275A FI913275A FI913275A FI913275A FI 913275 A FI913275 A FI 913275A FI 913275 A FI913275 A FI 913275A FI 913275 A FI913275 A FI 913275A FI 913275 A FI913275 A FI 913275A
Authority
FI
Finland
Prior art keywords
provides
sjukdomsmottstaondskraft
stimulating
administering
glucan
Prior art date
Application number
FI913275A
Other languages
English (en)
Other versions
FI913275A0 (fi
FI104537B (fi
Inventor
Gunnar Rorstad
Borre Robertson
Jan Raa
Original Assignee
Phillips Petroleum Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phillips Petroleum Co filed Critical Phillips Petroleum Co
Publication of FI913275A0 publication Critical patent/FI913275A0/fi
Publication of FI913275A publication Critical patent/FI913275A/fi
Application granted granted Critical
Publication of FI104537B publication Critical patent/FI104537B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Catching Or Destruction (AREA)
FI913275A 1990-07-06 1991-07-05 Menetelmä hiivaglukaanin valmistamiseksi FI104537B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54957590A 1990-07-06 1990-07-06
US54957590 1990-07-06

Publications (3)

Publication Number Publication Date
FI913275A0 FI913275A0 (fi) 1991-07-05
FI913275A true FI913275A (fi) 1992-01-07
FI104537B FI104537B (fi) 2000-02-29

Family

ID=24193557

Family Applications (1)

Application Number Title Priority Date Filing Date
FI913275A FI104537B (fi) 1990-07-06 1991-07-05 Menetelmä hiivaglukaanin valmistamiseksi

Country Status (12)

Country Link
US (1) US5401727A (fi)
EP (1) EP0466037B1 (fi)
JP (1) JP2828799B2 (fi)
AT (1) ATE160787T1 (fi)
AU (1) AU628752B2 (fi)
CA (1) CA2040374C (fi)
DE (1) DE69128308T2 (fi)
DK (1) DK0466037T3 (fi)
ES (1) ES2109929T3 (fi)
FI (1) FI104537B (fi)
GR (1) GR3026130T3 (fi)
NO (1) NO305705B1 (fi)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0665649B2 (ja) * 1991-02-01 1994-08-24 台糖株式会社 甲殻類の生体防御能増強剤、感染症予防ワクチン及び飼料
JP3522772B2 (ja) * 1991-05-21 2004-04-26 台糖株式会社 ワクチンの免疫効果増強剤
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
PT664671E (pt) * 1993-08-06 2003-01-31 Biotec Pharmacon Asa Racoes para animais compreendendo glucano de levedura
JPH08113539A (ja) * 1993-09-22 1996-05-07 Nippon Paper Ind Co Ltd 免疫増強剤及びその製造方法、並びにそれを用いた甲殻類及び魚類の養殖用飼料
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5871751A (en) * 1994-10-12 1999-02-16 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Renibacterium salmoninarum vaccine and method for its preparation
JP3744020B2 (ja) * 1995-04-14 2006-02-08 日本製紙株式会社 免疫増強剤並びにそれを含有する甲殻類、魚類及び家畜用飼料
AU718898B2 (en) * 1995-09-05 2000-04-20 Tetra Werke Dr. Rer. Nat. Ulrich Baensch Gmbh Anti-stress agents for aquatic animals
US5722346A (en) * 1996-04-17 1998-03-03 The Board Of Governors For Higher Education Smolting feed
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
AU6691598A (en) * 1997-04-18 1998-11-13 Immudyne, Inc. Gel delivery system for animal nutrition and health
ATE421883T1 (de) * 1998-09-14 2009-02-15 Nabi Biopharmaceuticals Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
US20040127458A1 (en) * 2000-11-06 2004-07-01 Hunter Kenneth W. Beta-glucan containing compositions, methods for manufacturing beta-glucans, and for manufacturing and using beta-glucans and conjugates thereof as vaccine adjuvants
US7816514B2 (en) 2001-02-16 2010-10-19 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US8222232B2 (en) * 2001-02-16 2012-07-17 Cargill, Incorporated Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass
US7923437B2 (en) * 2001-02-16 2011-04-12 Cargill, Incorporated Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
US7323140B2 (en) * 2001-03-28 2008-01-29 Handylab, Inc. Moving microdroplets in a microfluidic device
US6939864B1 (en) 2001-07-09 2005-09-06 Purdue Research Foundation Animal feed compositions and methods of using the same
JPWO2003039567A1 (ja) * 2001-11-06 2005-02-24 株式会社オリエントキャンサーセラピー 抗癌組成物
DE10222358A1 (de) * 2002-05-21 2003-12-11 Nutrinova Gmbh ß-Glucanhaltiges Sorbinsäurepräparat als Futtermittelzusatz in der Nutztieraufzucht
US7018986B2 (en) * 2002-09-20 2006-03-28 Immudyne Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
GB0225502D0 (en) * 2002-11-01 2002-12-11 Zoolife Internat Ltd Therapeutic and prophylactic preparations
GB0225503D0 (en) * 2002-11-01 2002-12-11 Zoolife Internat Ltd Gel feed
JP2004210895A (ja) * 2002-12-27 2004-07-29 Immudyne Japan:Kk 免疫機能を有する可能性β−グルカンの製造方法及び用途
AU2004207565B2 (en) * 2003-01-29 2009-04-23 Immudyne, Inc. Immunopotentiating agent for use in animals
GB2399752A (en) * 2003-03-26 2004-09-29 Micap Plc Pharmaceutical composition comprising a fungal cell or cell fragment as adjuvant
EP1711058B1 (en) 2004-01-23 2021-09-15 Eden Research Plc Methods of killing nematodes comprising the application of a terpene component
PL2338332T3 (pl) 2004-05-20 2014-07-31 Eden Research Plc Cząsteczka glukanu kapilarnego lub cząsteczka ściany komórkowej zamykająca składnik terpenowy
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US8007814B2 (en) * 2004-06-16 2011-08-30 University Of Massachusetts Therapy for lysosomal enzyme deficiencies
US7306818B2 (en) * 2005-01-03 2007-12-11 Promd Biotech Co., Ltd. Method for preventing and/or treating viral infection in aquatic animals
CA2912012C (en) 2005-05-05 2018-05-29 Sensient Flavors Inc. Production of beta-glucans and mannans
ATE526991T1 (de) * 2005-10-24 2011-10-15 Univ Massachusetts Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
AP2901A (en) 2005-11-30 2014-05-31 Eden Research Plc Compositions and methods comprising terpenes or terpene mixtures selected form thymol, eugenol, geraniol, citral, and L-carvone
EP2982244B1 (en) 2005-11-30 2020-11-18 Eden Research Plc Insecticidal capsules containing thymol and methods of making and using them
US20100322923A1 (en) * 2007-02-21 2010-12-23 Biotec Pharmacon Asa Medical Uses of Glucans
JP5153188B2 (ja) * 2007-03-30 2013-02-27 小林製薬株式会社 Ｔｈ１／Ｔｈ２バランス改善剤
US20090061049A1 (en) * 2007-08-28 2009-03-05 Vadood Azarm Feed compositions for aquatic animals and methods of making the same
WO2009058913A2 (en) * 2007-10-29 2009-05-07 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
EP2219655A2 (en) * 2007-11-13 2010-08-25 Biotec Pharmacon ASA Methods of treating or preventing inflammatory diseases of the intestinal tract
CA2705544A1 (en) * 2007-11-19 2009-05-28 Calanus As Bioactive copepod-compositions, processes for the production thereof, and use thereof to prevent or treat hosts infested by phylogenetically similar ectoparasites
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US20100267661A1 (en) * 2009-03-17 2010-10-21 Immudyne, Inc. Beta glucans and methods of use thereof
EP2550001B1 (en) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
IL265674B2 (en) 2010-03-24 2024-05-01 Phio Pharm Corp Rana disorder in cutaneous and fibrotic symptoms
US9242857B2 (en) 2010-08-14 2016-01-26 University Of Massachusetts Yeast cell wall particles for receptor-targeted nanoparticle delivery
WO2012120290A2 (en) 2011-03-04 2012-09-13 Sana Pharma As Cosmetic formulations
GB201220940D0 (en) 2012-11-21 2013-01-02 Eden Research Plc Method P
BR112016011711A2 (pt) 2013-11-21 2017-08-08 Eden Research Plc Composição pesticida, método para prepará-la e método para matar insetos
US20160304875A1 (en) 2013-12-04 2016-10-20 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
EP3137119B1 (en) 2014-04-28 2020-07-01 Phio Pharmaceuticals Corp. Methods for treating cancer using a nucleic acid targeting mdm2
JP2017514908A (ja) 2014-05-01 2017-06-08 アールエックスアイ ファーマシューティカルズ コーポレーション 核酸分子を利用する目の前部における障害の処置のための方法
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
WO2016100716A1 (en) 2014-12-18 2016-06-23 Vasant Jadhav Reversirtm compounds
GB201501793D0 (en) 2015-02-03 2015-03-18 Eden Research Plc Encapsulation of high potency active agents
WO2017007813A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
EP3138573A1 (en) 2015-07-09 2017-03-08 Danstar Ferment AG Compositions and methods for stimulating immune responses in human and/or animal
WO2017070151A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
CN106719136A (zh) * 2016-11-30 2017-05-31 蚌埠市渔歌农业科技有限公司 一种防治鲶鱼病害的养殖方法
JP6530846B1 (ja) * 2018-10-09 2019-06-12 アサヒグループホールディングス株式会社 免疫賦活剤及び感染予防方法
JP2023501445A (ja) 2019-11-08 2023-01-18 フィオ ファーマシューティカルズ コーポレーション 免疫治療のためのブロモドメイン含有タンパク質４（ｂｒｄ４）を標的とする化学修飾されたオリゴヌクレオチド
AU2022278209A1 (en) * 2021-05-21 2023-11-09 Asahi Group Holdings, Ltd. Immunostimulator and glucan composition production method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301848A (en) * 1962-10-30 1967-01-31 Pillsbury Co Polysaccharides and methods for production thereof
GB2076418A (en) * 1980-05-22 1981-12-02 Sankyo Co Hydrolyzed polysaccharide
SE456911B (sv) * 1983-12-19 1988-11-14 Olle Larm Vattenloeslig, aminerad beta-1,3-bunden d-glukan och makrofagstimulerande komposition innehaallande densamma
JPS6120561A (ja) * 1984-07-09 1986-01-29 住友ベークライト株式会社 医療用吸着剤
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
JPS6337801A (ja) * 1986-07-31 1988-02-18 Matsushita Electric Ind Co Ltd タ−ンテ−ブル
CA1330303C (en) * 1989-02-20 1994-06-21 Libor Henry Nikl Composition and process to enhance the efficacy of a fish vaccine

Also Published As

Publication number Publication date
EP0466037A3 (en) 1992-10-28
EP0466037B1 (en) 1997-12-03
JPH04253703A (ja) 1992-09-09
AU628752B2 (en) 1992-09-17
DE69128308T2 (de) 1998-03-26
EP0466037A2 (en) 1992-01-15
NO912645L (no) 1992-01-07
NO305705B1 (no) 1999-07-12
ATE160787T1 (de) 1997-12-15
DE69128308D1 (de) 1998-01-15
NO912645D0 (no) 1991-07-05
FI913275A0 (fi) 1991-07-05
JP2828799B2 (ja) 1998-11-25
AU7933891A (en) 1992-01-23
GR3026130T3 (en) 1998-05-29
CA2040374A1 (en) 1992-01-07
US5401727A (en) 1995-03-28
CA2040374C (en) 1998-06-16
DK0466037T3 (da) 1998-08-10
FI104537B (fi) 2000-02-29
ES2109929T3 (es) 1998-02-01

Similar Documents

Publication Publication Date Title
FI913275A0 (fi) Foerfarande foer foerbaettring av sjukdomsmottstaondskraft.
ZA91559B (en) Vaccines against cancer and infectious diseases
DK0714444T3 (da) Dæmpning af en immundominant epitop i et antigen til anvendelse i plante-, dyre- og humanvacciner og immunbehandlinger
ATE390933T1 (de) Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
ID22994A (id) Senyawa aminoalkil glikosamina fosfat dan penggunaannya sebagai adjuvan dan pemicu kekebalan
GR3029774T3 (en) Method of preparing a radioactive rhenium complex solution.
IL95867A0 (fi)
ID21338A (id) Metoda untuk menghasilkan kekebalan aktif dengan vaksin gabungan
DE69333730D1 (de) Impfstoff, der acemannan als adjuvans enthält
DE68917138T2 (de) Toleranzinduktion gegenüber einem fremdantigen.
PT636030E (pt) Vacina de bacterina-toxoide de pasteurella haemolytica tipo a-1
BR9814556A (pt) Cepas isoladas de staphylococcus aureus e vacinas fabricadas a partir das mesmas
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza
ATA211388A (de) Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobuling-h|ltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
MC1653A1 (fr) Antigene viral,son procede d'obtention et son application diagnostique et therapeutique
NZ337730A (en) use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: AS BIOTECH-MACKZYMAL

MA Patent expired